The resilience of the United States biotechnology supply chain has become a national priority as global disruptions, resource constraints, and geopolitical pressures increasingly threaten the continuity of critical biomedical products. Biotech supply chains spanning raw material sourcing, bioprocessing, cold-chain logistics, and therapeutic distribution are uniquely complex, highly regulated, and sensitive to environmental variability. Traditional management systems, characterized by fragmented data, limited interoperability, and reactive decision-making, are no longer sufficient in a landscape defined by accelerated innovation cycles and rising international competition. Digital transformation offers a strategic pathway to reinforce supply chain robustness by integrating advanced analytics, automation, and real-time visibility across end-to-end operations. This article examines how emerging digital technologies can enhance supply chain resilience while strengthening U.S. leadership in biotechnology manufacturing and distribution. At a broad level, we analyze structural vulnerabilities including dependence on foreign suppliers, inconsistent quality monitoring, and siloed information flows that hinder operational agility and national preparedness. Narrowing the focus, the article explores digital solutions such as AI-enabled demand forecasting, blockchain-based traceability architectures, digital twins for biomanufacturing optimization, sensor-driven cold-chain monitoring, and cloud-integrated risk intelligence systems. These technologies collectively support predictive disruption management, improved regulatory compliance, and strengthened coordination among federal agencies, private manufacturers, and logistics partners. By outlining a digital transformation roadmap grounded in infrastructure modernization, data governance, and multistakeholder collaboration, the article provides a strategic framework for building a resilient, transparent, and responsive biotech supply chain. Such modernization is essential not only for mitigating future disruptions but also for advancing U.S. competitiveness in a rapidly evolving global bioeconomy.
Nathanael Jiya (Wed,) studied this question.